Ionis Pharmaceuticals, Inc. (IONS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Carlsbad, CA, United States. El CEO actual es Brett Monia.
IONS tiene fecha de IPO 1991-05-17, 1,069 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $12.68B.
Ionis Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, specializing in the discovery and development of RNA-targeted therapeutics. The company markets approved treatments including SPINRAZA for spinal muscular atrophy, TEGSEDI for hereditary transthyretin-mediated amyloidosis, and WAYLIVRA for familial lipid disorders, while maintaining a robust pipeline of Phase 3 candidates targeting rare genetic diseases, cardiovascular conditions, and neurological disorders. Through strategic collaborations with major pharmaceutical partners including Biogen, AstraZeneca, Bayer, GlaxoSmithKline, Novartis, and Roche, Ionis is advancing its platform across metabolic diseases, infectious diseases, renal diseases, and oncology.
